EORTC protocols in <font color="red">prostatic_1</font> <font color="red">cancer_1</font> <font color="red">._1</font> An interim report . 
<br>
<br> Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with <font color="red">prostatic_1</font> <font color="red">cancer_1</font> in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial . Although the follow up is still short , no <font color="red">superiority_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">other_1</font> <font color="red">drugs_1</font> <font color="red">over_1</font> <font color="red">Stilboestrol_1</font> had appeared so far with regard to either <font color="red">objective_1</font> <font color="red">response_1</font> <font color="red">or_1</font> <font color="red">significant_1</font> <font color="red">side_1</font> <font color="red">effects_1</font> <font color="red">apart_1</font> <font color="red">from_1</font> <font color="red">gynaecomastia_1</font> <font color="red">._1</font> In the third trial , patients with advanced disease no longer responsive to hormonal treatment were randomized to either Adriamycin or Procarbazine . <font color="red">Toxicity_4</font> <font color="red">and_4</font> <font color="red">early_4</font> <font color="red">death_4</font> were particularly frequent in Procarbazine treated patients , whereas most patients progressed in both treatment groups .